New Three-Drug cocktail aims to fight tough lung cancer
NCT ID NCT07318883
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding an experimental drug called HLX07 to standard immunotherapy and chemotherapy helps people with advanced squamous non-small cell lung cancer. About 720 adults with stage 3B/4 disease will receive either the new combo or a placebo with standard treatment. The goal is to see if the new combination shrinks tumors and extends life better than current options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HLX07 (anti-EGFR antibody) plus serplulimab and chemotherapy
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for advanced squamous lung cancer, potentially improving tumor shrinkage and delaying disease progression.
- What could go wrong
- This is an early-to-mid stage trial (phase 2/3) with 720 participants. The experimental drug may not prove more effective than existing treatments, and side effects from combining multiple drugs could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.